AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35013093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of curcumin, resveratrol, zinc, magnesium, selenium, and vitamin D
Number of subjects: 48
Study 35013093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 34088701 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human parathyroid hormone (PTH) (1-84)
Number of subjects: 0
Study 34088701 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 32016520 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty grading score (low, medium, high) based on spleen weight, esophagogastric varices, and INR
Number of subjects: 272
Study 32016520 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty grading score
Number of subjects: 272
Study 32016520 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis of the scoring system
Number of subjects: 272
Study 32016520 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of the scoring system
Number of subjects: 272
Study 32016520 — intervention group
Group type: COMPARATOR
Intervention: Comparison of difficulty score with previous grading system
Number of subjects: 272
Study 34957958 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial induction therapy (MIT)
Number of subjects: 68
Study 34957958 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug treatments and instrumental physical therapy)
Number of subjects: 68
Study 34913362 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC therapy (infused at weeks 6 and 7 after transplantation, tacrolimus withdrawal at week 8)
Number of subjects: 54
Study 34913362 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC therapy
Number of subjects: 54
Study 34913362 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus dose (control group)
Number of subjects: 54
Study 33059096 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vibration training (LVT) during standardised rehabilitation, n=16
Number of subjects: 30
Study 33059096 — intervention group
Group type: COMPARATOR
Intervention: Control group with standardised rehabilitation alone, n=14
Number of subjects: 30
Study 33259244 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: vinorelbine 60 mg/m2 day 1 + day 8 in the first cycle followed by 80 mg/m2 day 1 + day 8 in the following cycles + capecitabine 1000 mg/m2 twice a day for days 1–14
Number of subjects: 120
Study 33259244 — intervention group
Group type: COMPARATOR
Intervention: Arm B: vinorelbine 50 mg three times a week + capecitabine 1000 mg/m2 twice a day for days 1–14
Number of subjects: 120
Study 36142909 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 61
Study 36142909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 35921175 — intervention group
Group type: EXPERIMENTAL
Intervention: mChemotherapy program (6-week duration, includes self-regulation activities and nurse-led support)
Number of subjects: 94
Study 35921175 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 94
Study 32074743 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital hereditary hearing loss (CHHL) patients
Number of subjects: 14
Study 34503866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg, increased to 60 mg if BP not controlled, with possible hydrochlorothiazide 12.5 mg combination
Number of subjects: 241
Study 34503866 — intervention group
Group type: COMPARATOR
Intervention: Perindopril arginine 2.5 mg, increased to 5 mg if BP not controlled, with possible indapamide 1.25 mg combination
Number of subjects: 241
Study 34503866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 30 to 60 mg with possible hydrochlorothiazide 12.5 mg combination
Number of subjects: 241
Study 34503866 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 2.5 to 5 mg with possible indapamide 1.25 mg combination
Number of subjects: 241
Study 34503866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 241
Study 33545751 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil combined with tanshinone IIa injection (Group C)
Number of subjects: 300
Study 33545751 — intervention group
Group type: COMPARATOR
Intervention: Alprostadil (Group A)
Number of subjects: 300
Study 33545751 — intervention group
Group type: COMPARATOR
Intervention: Tanshinone IIa injection (Group B)
Number of subjects: 300
Study 32058832 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 0
Study 32058832 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclass preparation and student accountability as part of TBL
Number of subjects: 0
Study 35904188 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Type Natriuretic Peptide (BNP)
Number of subjects: 799
Study 35904188 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP + CHADS2
Number of subjects: 799
Study 35904188 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP + CHA2 DS2-VASc
Number of subjects: 799
Study 35904188 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP + R2 CHADS2
Number of subjects: 799
Study 33512318 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based intervention (Bao Hu San) including unintentional child injury and parenting education
Number of subjects: 2920
Study 33512318 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only parenting education
Number of subjects: 2920
Study 32053137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus neoadjuvant chemotherapy (4 cycles of pembrolizumab in combination with weekly paclitaxel followed by AC)
Number of subjects: 250
Study 32053137 — intervention group
Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy (NACT)
Number of subjects: 250
Study 32053137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus neoadjuvant chemotherapy
Number of subjects: 250
Study 35231608 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized rTMS
Number of subjects: 0
Study 35231608 — intervention group
Group type: COMPARATOR
Intervention: Unsynchronized rTMS
Number of subjects: 0
Study 33033308 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise regression
Number of subjects: 201
Study 33033308 — intervention group
Group type: EXPERIMENTAL
Intervention: Least absolute shrinkage and selection operator (LASSO)
Number of subjects: 201
Study 33033308 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosting
Number of subjects: 201
Study 33033308 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate adaptive regression splines (MuARS)
Number of subjects: 201
Study 33033308 — intervention group
Group type: COMPARATOR
Intervention: All four models (Stepwise regression, LASSO, Boosting, MuARS)
Number of subjects: 201
Study 34389558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) alone or in combination with ipilimumab (IPI) or IPI alone
Number of subjects: 0
Study 34389558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO)
Number of subjects: 0
Study 34389558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined assessment of TMB, inflammatory gene expression signature, and BRAF mutation status
Number of subjects: 0
Study 32323707 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation without extension of margins (Group A)
Number of subjects: 30
Study 32323707 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation with at least 3mm extension of margins (Group B)
Number of subjects: 30
Study 32323707 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated lesions)
Number of subjects: 30
Study 36451419 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 24 supervised training sessions (strength and aerobic) for 12 weeks (2 60‐minutes sessions per week)
Number of subjects: 100
Study 36451419 — intervention group
Group type: EXPERIMENTAL
Intervention: Gametherapy group (GG) - exercise using gametherapy
Number of subjects: 100
Study 36451419 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG)
Number of subjects: 100
Study 32599652 — intervention group
Group type: EXPERIMENTAL
Intervention: Vutrisiran (5-300 mg)
Number of subjects: 80
Study 33956213 — intervention group
Group type: EXPERIMENTAL
Intervention: On-body injector (OBI)
Number of subjects: 308
Study 33956213 — intervention group
Group type: COMPARATOR
Intervention: Pre-filled syringe (PS)
Number of subjects: 308
Study 32839797 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE + Vit E
Number of subjects: 100
Study 32839797 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE
Number of subjects: 100
Study 32839797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vit E
Number of subjects: 100
Study 32839797 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 35190440 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy conservation education intervention (structured programme over 12 weeks with three face-to-face sessions, one booster session, and a booklet)
Number of subjects: 126
Study 35190440 — intervention group
Group type: COMPARATOR
Intervention: Usual care from healthcare providers and a booklet at the end of the study
Number of subjects: 126
Study 33952216 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% TTO gel adjunctive to SRP
Number of subjects: 30
Study 33952216 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (Control Group)
Number of subjects: 30
Study 33753755 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily training regimen over 5 days
Number of subjects: 47
Study 33753755 — intervention group
Group type: COMPARATOR
Intervention: Intensive schedule of 5 sessions delivered over 2 days
Number of subjects: 47
Study 32616109 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based spatial cognitive training (VR-SCT)
Number of subjects: 56
Study 32616109 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 56
Study 34158656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous secretin
Number of subjects: 15
Study 34158656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 32304422 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic ex-vivo perfusion of cardiac allografts
Number of subjects: 0
Study 32304422 — intervention group
Group type: COMPARATOR
Intervention: Cold storage
Number of subjects: 0
Study 35169007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerinetide treatment
Number of subjects: 184
Study 35169007 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of iatrogenic infarcts
Number of subjects: 184
Study 35169007 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lesion counts
Number of subjects: 184
Study 33619181 — intervention group
Group type: EXPERIMENTAL
Intervention: nntcalc R package and web application for computing NNT
Number of subjects: 0
Study 33619181 — intervention group
Group type: EXPERIMENTAL
Intervention: nntcalc R package and web application
Number of subjects: 0
Study 35294778 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg every 2 weeks)
Number of subjects: 81
Study 35294778 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 81
Study 35294778 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab monotherapy
Number of subjects: 81
Study 35294778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention groups (Evolocumab and Atorvastatin)
Number of subjects: 81
Study 35294778 — intervention group
Group type: COMPARATOR
Intervention: Control (Atorvastatin and Evolocumab)
Number of subjects: 81
Study 34710138 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive news segments
Number of subjects: 62
Study 34710138 — intervention group
Group type: COMPARATOR
Intervention: Neutral news segments
Number of subjects: 62
Study 32306153 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (300 mmol sodium/day)
Number of subjects: 15
Study 32306153 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (20 mmol sodium/day)
Number of subjects: 15
Study 35302504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonguided mindfulness mobile app (8-week program)
Number of subjects: 587
Study 35302504 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 587
Study 33001402 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital version of TMT-A
Number of subjects: 50
Study 33001402 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital version of TMT-B
Number of subjects: 50
Study 33001402 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital version of CWIT
Number of subjects: 50
Study 33001402 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual usage of computer
Number of subjects: 50
Study 33001402 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual usage of smartphone
Number of subjects: 50
Study 33001402 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability of TMT-B
Number of subjects: 50
Study 34758516 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol prophylaxis
Number of subjects: 0
Study 34758516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34758516 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic burden (ACB)
Number of subjects: 0
Study 32888185 — intervention group
Group type: EXPERIMENTAL
Intervention: MOGS (myrtle and oak gall suppository)
Number of subjects: 120
Study 32888185 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 120
Study 32888185 — intervention group
Group type: EXPERIMENTAL
Intervention: MOGS and Metronidazole
Number of subjects: 120
Study 32888185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 36449413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanemab (10 mg/kg every 2 weeks)
Number of subjects: 1795
Study 36449413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1795
Study 36449413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanemab
Number of subjects: 1795
Study 33429753 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin combined with hypersensitive cardiac troponin T (hs‐cTnT)
Number of subjects: 0
Study 33429753 — intervention group
Group type: COMPARATOR
Intervention: Cardiac troponin I (cTnI)
Number of subjects: 0
Study 33327993 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-compatible incubator
Number of subjects: 120
Study 33327993 — intervention group
Group type: COMPARATOR
Intervention: Conventional neonatal transfer incubator
Number of subjects: 120
Study 34798036 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab (105 mg subcutaneous once every 4 weeks)
Number of subjects: 358
Study 34798036 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (160 mg on day 1, 80 mg at week 2, 40 mg at weeks 4, 6, and 8)
Number of subjects: 358
Study 34798036 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 358
Study 34798036 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 358
Study 34798036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 33387727 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg orally, once-daily, until disease progression or voluntary withdrawal
Number of subjects: 479
Study 36102425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue ties
Number of subjects: 30
Study 36102425 — intervention group
Group type: COMPARATOR
Intervention: No tongue ties (control)
Number of subjects: 30
Study 34673898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab injections for PDR
Number of subjects: 170
Study 34501561 — intervention group
Group type: EXPERIMENTAL
Intervention: Free face mask distribution
Number of subjects: 9
Study 34501561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no face mask distribution)
Number of subjects: 9
Study 32217340 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU cholecalciferol/2wks
Number of subjects: 56
Study 32217340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 35511184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1 mg/m2 IV) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2 (Bor-HDM)
Number of subjects: 300
Study 35511184 — intervention group
Group type: COMPARATOR
Intervention: High-dose melphalan alone (200 mg/m2 IV) (HDM)
Number of subjects: 300
Study 32656890 — intervention group
Group type: EXPERIMENTAL
Intervention: Diversion pouch bacterial contamination
Number of subjects: 233
Study 32656890 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet components bacterial contamination
Number of subjects: 233
Study 37194567 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly POEM for 7 weeks
Number of subjects: 296
Study 37194567 — intervention group
Group type: COMPARATOR
Intervention: No POEM during this period
Number of subjects: 296
Study 34105515 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT use within the first year after BRS implantation
Number of subjects: 2973
Study 34105515 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT use between 1 and 3 years after BRS implantation
Number of subjects: 2973
Study 34105515 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT use
Number of subjects: 2973
Study 32438905 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 10% MVIC
Number of subjects: 55
Study 32438905 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions at 25% MVIC
Number of subjects: 55
Study 32438905 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 55
Study 36385019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuestra Comunidad Saludable intervention
Number of subjects: 100
Study 36385019 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 100
Study 34628811 — intervention group
Group type: EXPERIMENTAL
Intervention: High Frequency Jet Ventilation (HFJV)
Number of subjects: 60
Study 34628811 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Positive Pressure Ventilation (IPPV)
Number of subjects: 60
Study 32823519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence-synchronous music
Number of subjects: 54
Study 32823519 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartrate-synchronous music
Number of subjects: 54
Study 33510313 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg/day
Number of subjects: 190
Study 33510313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg/day
Number of subjects: 190
Study 33510313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 33221468 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscotrabeculotomy-trabeculectomy (VTT)
Number of subjects: 17
Study 33221468 — intervention group
Group type: COMPARATOR
Intervention: Conventional trabeculotomy-trabeculectomy (CTT)
Number of subjects: 17
Study 34952738 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Number of subjects: 20
Study 34952738 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Number of subjects: 20
Study 34952738 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing (standard of care)
Number of subjects: 20
Study 34952738 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP and PRGF
Number of subjects: 20
Study 34172030 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-GP intervention
Number of subjects: 108
Study 34172030 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 108
Study 35298906 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (600 mg twice daily)
Number of subjects: 349
Study 35298906 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (administered per institutional guidelines)
Number of subjects: 349
Study 35298906 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (in intention-to-treat population)
Number of subjects: 349
Study 35298906 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (in intention-to-treat population)
Number of subjects: 349
Study 35298906 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 349
Study 35298906 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 349
Study 34067028 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV and core-exercise (WBVEx)
Number of subjects: 3
Study 34067028 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-exercise alone (Ex)
Number of subjects: 3
Study 34067028 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study 36323186 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 0
Study 36323186 — intervention group
Group type: COMPARATOR
Intervention: Traditional Care (TC)
Number of subjects: 0
Study 32924721 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw muscle palpation (PtP)
Number of subjects: 779
Study 32924721 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional PtP
Number of subjects: 779
Study 32924721 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized PtP
Number of subjects: 779
Study 33277806 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid
Number of subjects: 150
Study 33277806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,2-propanediol
Number of subjects: 150
Study 33277806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-propanol
Number of subjects: 150
Study 33277806 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 36167669 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting 1-2 times/week
Number of subjects: 99713
Study 36167669 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic MVPA without weightlifting
Number of subjects: 99713
Study 36167669 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting (without adjustment for MVPA)
Number of subjects: 99713
Study 36167669 — intervention group
Group type: COMPARATOR
Intervention: Weightlifting
Number of subjects: 99713
Study 33595920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated irrigation (UAI) for 60s with an Irrisafe tip (n = 28)
Number of subjects: 56
Study 33595920 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation (LAI) using a pulsed Er:YAG laser for 60s (n = 28)
Number of subjects: 56